LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 80

Search options

  1. Book ; Online: Assessment and management of chronic cough

    McCrory, Douglas C

    (Comparative effectiveness review ; no. 100 ; AHRQ publication ; no. 13-EHC032-EF)

    2013  

    Abstract: OBJECTIVES: Cough is the most common complaint for patients seeking medical attention in the United States. Although the most common cause of cough is acute self-limited viral infections, chronic cough (cough that lasts more than 4 weeks in children <14 ... ...

    Institution United States. / Agency for Healthcare Research and Quality.
    Duke University Evidence-based Practice Center.
    Effective Health Care Program (U.S.)
    Author's details prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; investigators, Douglas C. McCrory ... [et al.]
    Series title Comparative effectiveness review ; no. 100
    AHRQ publication ; no. 13-EHC032-EF
    Abstract OBJECTIVES: Cough is the most common complaint for patients seeking medical attention in the United States. Although the most common cause of cough is acute self-limited viral infections, chronic cough (cough that lasts more than 4 weeks in children <14 years of age or more than 8 weeks in adolescents and adults) has a significant impact on quality of life and is responsible for up to 38 percent of pulmonary outpatient visits. Furthermore, a treatable cause is absent in up to 46 percent of patients with chronic cough despite a thorough diagnostic investigation. The comparative value of tools for assessing cough and the comparative effectiveness of treatments for unexplained or refractory cough are uncertain. DATA SOURCES: We searched PubMed(r), Embase(r), and the Cochrane Database of Systematic Reviews (June 4, 2012) for relevant English-language comparative studies. REVIEW METHODS: Two investigators screened each abstract and full-text article for inclusion, abstracted data, rated quality and applicability, and graded evidence. Random-effects models were used to compute summary estimates of effects. We supplemented the meta-analysis of direct comparisons with a mixed treatment meta-analysis that incorporated data from placebo comparisons and head-to-head comparisons. RESULTS: To evaluate instruments for assessing cough, we considered the dimensions of cough frequency, cough severity, and cough-specific quality of life (QOL). We sought to measure the validity, reliability, and responsiveness of various instruments used to assess each of these dimensions. Seventy-eight studies (5,927 subjects) evaluated instruments for assessing cough. The Leicester Cough Questionnaire (LCQ) and Cough-specific Quality of Life Questionnaire (CQLQ) were the most widely studied instruments in adults; there is moderate strength of evidence (SOE) to support both the LCQ's and the CQLQ's validity in assessing severity/QOL of cough. For pediatric populations, there is moderate SOE to support the Parent Cough-specific Quality of Life questionnaire's (PC-QOL) validity in assessing severity/QOL of cough. Electronic recording devices are accurate for assessing cough frequency, but show variable correlation with other tools. Although visual analog scales (VAS) are easy to administer and have face validity, we did not identify any studies to formally validate their accuracy in assessing cough. We identified no studies exploring the impact of cough assessment instruments on therapeutic efficacy or patient outcome efficacy. Forty-eight studies (2,923 patients) evaluated 67 therapeutic comparisons for patients with chronic cough. Classes of drugs evaluated included opioid, anesthetic, and nonopioid/nonanesthetic antitussives; expectorant and mucolytic protussives; antihistamines; antibiotics; inhaled corticosteroids; and inhaled anticholinergics. The opioid and certain nonopioid/nonanesthetic antitussives most frequently demonstrated efficacy for managing chronic cough in adults. In particular, codeine and dextromethorphan reduced cough severity and frequency. Relative to placebo, the effect of dextromethorphan on cough severity was 0.54 (95% confidence interval [CI], 0.27 to 0.80; p=0.0008), and the effect of opiates was 0.63 (95% CI, 0.40 to 0.86; p<0.0001). Relative to placebo, the effect of dextromethorphan on cough frequency was 0.40 (95% CI, 0.18 to 0.85; p=0.0248), and the effect of codeine was 0.57 (95% CI, 0.36 to 0.91; p=0.0260). However, due to inconsistency and imprecision of results, and small numbers of direct comparisons, the overall SOE is insufficient to draw firm conclusions about the comparative effectiveness of these agents. Very few studies evaluated nonpharmacological therapies (two studies) or the management of cough in children (three studies). CONCLUSIONS: Several instruments for assessing cough severity, frequency, and impact on cough-specific quality of life show good internal consistency but variable correlation with other cough measurement tools, meaning that a number of instruments are precise but their accuracy is less clear. Although the evidence is sparse, the opioid and certain nonopioid/nonanesthetic antitussives most frequently demonstrated efficacy for managing the symptom of chronic cough in adults. Our review highlights the need for further studies in patient populations with unexplained or refractory chronic cough as determined by current diagnostic and empiric treatment recommendations. Further, it shows the need for more systematic design and reporting of these studies and assessment of their patient-centered outcomes. This is in contrast to the more extensive literature on the management of acute cough.
    MeSH term(s) Cough/diagnosis ; Cough/therapy ; Chronic Disease
    Keywords United States
    Language English
    Size 1 online resource (1 PDF file (1 v. (various pagings)) :, ill.)
    Publisher Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services
    Publishing place Rockville, Md
    Document type Book ; Online
    Note Contract No. 290-2007-10066-I. ; "January 2013."
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  2. Article ; Online: Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis.

    Stubberud, Anker / Flaaen, Nikolai Melseth / McCrory, Douglas C / Pedersen, Sindre Andre / Linde, Mattias

    Pain

    2019  Volume 160, Issue 4, Page(s) 762–772

    Abstract: Based on few clinical trials, flunarizine is considered a first-line prophylactic treatment for migraine in several guidelines. In this meta-analysis, we examined the pooled evidence for its effectiveness, tolerability, and safety. Prospective randomized ...

    Abstract Based on few clinical trials, flunarizine is considered a first-line prophylactic treatment for migraine in several guidelines. In this meta-analysis, we examined the pooled evidence for its effectiveness, tolerability, and safety. Prospective randomized controlled trials of flunarizine as a prophylaxis against migraine were identified from a systematic literature search, and risk of bias was assessed for all included studies. Reduction in mean attack frequency was estimated by calculating the mean difference (MD), and a series of secondary outcomes-including adverse events (AEs)-were also analyzed. The database search yielded 879 unique records. Twenty-five studies were included in data synthesis. We scored 31/175 risk of bias items as "high," with attrition as the most frequent bias. A pooled analysis estimated that flunarizine reduces the headache frequency by 0.4 attacks per 4 weeks compared with placebo (5 trials, 249 participants: MD -0.44; 95% confidence interval -0.61 to -0.26). Analysis also revealed that the effectiveness of flunarizine prophylaxis is comparable with that of propranolol (7 trials, 1151 participants, MD -0.08; 95% confidence interval -0.34 to 0.18). Flunarizine also seems to be effective in children. The most frequent AEs were sedation and weight increase. Meta-analyses were robust and homogenous, although several of the included trials potentially suffered from high risk of bias. Unfortunately, reporting of AEs was inconsistent and limited. In conclusion, pooled analysis of data from partially outdated trials shows that 10-mg flunarizine per day is effective and well tolerated in treating episodic migraine-supporting current guideline recommendations.
    MeSH term(s) Databases, Bibliographic ; Flunarizine/therapeutic use ; Histamine H1 Antagonists/therapeutic use ; Humans ; Migraine Disorders/prevention & control ; Randomized Controlled Trials as Topic
    Chemical Substances Histamine H1 Antagonists ; Flunarizine (R7PLA2DM0J)
    Language English
    Publishing date 2019-02-01
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 193153-2
    ISSN 1872-6623 ; 0304-3959
    ISSN (online) 1872-6623
    ISSN 0304-3959
    DOI 10.1097/j.pain.0000000000001456
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Antiepileptics in migraine prophylaxis: an updated Cochrane review.

    Mulleners, Wim M / McCrory, Douglas C / Linde, Mattias

    Cephalalgia : an international journal of headache

    2015  Volume 35, Issue 1, Page(s) 51–62

    Abstract: Introduction: The efficacy of several antiepileptics in the preventive treatment of episodic migraine in adults has been systematically reviewed. Because many trial reports have been published since then, an updated systematic review was warranted.: ... ...

    Abstract Introduction: The efficacy of several antiepileptics in the preventive treatment of episodic migraine in adults has been systematically reviewed. Because many trial reports have been published since then, an updated systematic review was warranted.
    Methods: We searched the Cochrane Central Register of Controlled Trials, PubMed/MEDLINE (1966 to January 15, 2013), MEDLINE In-Process (current week, January 15, 2013), and EMBASE (1974 to January 15, 2013) and hand-searched Headache and Cephalalgia through January 2013. Prospective, controlled trials of antiepileptics taken regularly to prevent the occurrence of migraine attacks, to improve migraine-related quality of life, or both, were selected.
    Results: Mean headache frequency on topiramate and sodium valproate is significantly lower than placebo. Likewise, topiramate and divalproex demonstrated favorable results for the proportion of subjects with ≥ 50% reduction of migraine attacks. For topiramate, 100 mg and 200 mg outperformed 50 mg, but this was paralleled by a higher adverse event rate. For valproate/divalproex, a dose-effect correlation could not be established. There was no unequivocal evidence of efficacy for any of the other antiepileptics.
    Conclusion: Topiramate, sodium valproate and divalproex are effective prophylactic treatments for episodic migraine in adults. In contrast to previous reports, there is insufficient evidence to further support the use of gabapentin.
    MeSH term(s) Anticonvulsants/therapeutic use ; Humans ; Migraine Disorders/prevention & control
    Chemical Substances Anticonvulsants
    Language English
    Publishing date 2015-01
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 604567-4
    ISSN 1468-2982 ; 0333-1024
    ISSN (online) 1468-2982
    ISSN 0333-1024
    DOI 10.1177/0333102414534325
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book ; Online: Pulmonary arterial hypertension

    McCrory, Douglas C

    screening, management, and treatment

    (Comparative effectiveness review ; number 117 ; AHRQ publication ; no. 13-EHC087-EF)

    2013  

    Abstract: OBJECTIVES: Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with increased pulmonary vascular resistance that, if unrelieved, progresses to right ventricular pressure overload, dysfunction, right heart failure, and ... ...

    Institution Duke University Evidence-based Practice Center,
    Effective Health Care Program (U.S.),
    United States. / Agency for Healthcare Research and Quality,
    Author's details prepared for, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, 540 Gaither Road, Rockville, MD 20850, www.ahrq.gov ; prepared by, Duke Evidence-based Practice Center, Durham, NC ; investigators, Douglas C. McCrory [and fifteen others]
    Series title Comparative effectiveness review ; number 117
    AHRQ publication ; no. 13-EHC087-EF
    Abstract OBJECTIVES: Pulmonary arterial hypertension (PAH) is a rare and progressive disease associated with increased pulmonary vascular resistance that, if unrelieved, progresses to right ventricular pressure overload, dysfunction, right heart failure, and premature death. PAH is more prevalent in some populations, thereby warranting screening of asymptomatic individuals. This review seeks to evaluate the comparative validity, reliability, and feasibility of echocardiography and biomarker testing for the screening, diagnosis, and management of PAH; to clarify whether the use of echocardiography or biomarkers affects decisionmaking and clinical outcomes; and to determine which medications are effective for treating PAH and whether combination therapy is more effective than monotherapy. DATA SOURCES: We searched PubMed(r), Embase(r), and the Cochrane Database of Systematic Reviews for relevant English-language comparative studies. REVIEW METHODS: Two investigators screened each abstract and full-text article for inclusion, abstracted data, rated quality and applicability, and graded the strength of evidence. Random-effects models were used to compute summary estimates of effect where several similar studies provided estimates. RESULTS: Sixty studies involving 7,096 patients evaluated biomarker tests, echocardiography, or both to screen for PAH. Symptom status of study populations consisted of asymptomatic (3 studies; 481 patients), symptomatic (41 studies; 4,394 patients), mixed (8 studies; 1,186 patients), and symptoms not described (8 studies; 1,035 patients). N-terminal pro-B-type natriuretic peptide (NT-proBNP) showed moderate correlation with right heart catheterization (RHC) hemodynamic measures and a great deal of variability between studies in its diagnostic accuracy and discrimination; however, one good-quality prospective cohort study suggested that biomarker testing with NT-proBNP might be useful in ruling out PAH in patients with symptoms suggestive of PAH who have elevated systolic pulmonary artery pressure (sPAP) by echocardiography. No data are available regarding combined echocardiography and biomarker screening in asymptomatic patients at high risk for PAH. Echocardiography estimates of pulmonary artery pressures (sPAP, tricuspid gradient [TG], and tricuspid regurgitant jet velocity [TRV]) and PVR (TRV/velocity-time integral of right ventricular outflow tract [VTIRVOT]) demonstrated good accuracy in screening for PAH, but accuracy varied with the prevalence of PAH in study populations. Ninety-nine studies involving 8,655 patients evaluated biomarker tests, echocardiography, or both to evaluate severity or prognosis and followed progression of disease or response to therapy. B-type natriuretic peptide (BNP) showed moderate correlation with most RHC measures (mean pulmonary artery pressure [mPAP], PVR, cardiac index, right atrial pressure [RAP]) and clinical measures of disease severity (6-minute walk distance [6MWD]) and showed weak correlation with pulmonary capillary wedge pressure (PCWP), indicating that BNP levels alone could not serve as an accurate surrogate marker for disease severity. Echocardiography-derived sPAP showed strong correlation with RHC-sPAP with a precise summary effect estimate, although there was a great deal of heterogeneity of results among individual studies. BNP level (summary hazard ratio [HR] 2.42; 95% confidence interval [CI], 1.72 to 3.41) and presence of pericardial effusion were strong predictors of mortality (summary HR 2.43; 95% CI, 1.57 to 3.77) RA size and uric acid were also predictive of mortality, but fractional area change (FAC) showed no significant ability to predict mortality, and data on TAPSE were insufficient. Thirty-seven studies involving 4,192 patients assessed the effectiveness of drug treatments for PAH in adults. Few deaths were observed in these limited duration studies, leading to wide CIs and lack of statistical power to detect a mortality difference associated with treatment. All drug classes demonstrated increases in 6WMD when compared with placebo, but comparisons between agents were inconclusive. Combination therapy also showed improved 6WMD compared with monotherapy, but the diversity of treatment regimens and the small number of combination therapy trials again make comparisons between specific regimens inconclusive. The odds ratio (OR) of hospitalization was lower in patients taking endothelin receptor antagonists or phosphodiesterase-5 inhibitors compared with placebo (OR 0.34 and 0.48, respectively), while the reduction in patients taking prostanoids compared with placebo was similar but not statistically significant. Each drug class showed a favorable impact on at least two of the three hemodynamic outcomes: cardiac index, mPAP, and PVR. The applicability of these findings is limited by the relative lack of diagnostic studies among asymptomatic patients and, in prognostic and diagnostic studies, inadequate description and apparent diversity of disease etiology and severity. CONCLUSIONS: Further confirmation is needed to determine if the combination of echocardiography and the biomarker NT-proBNP is sufficiently accurate to rule out PAH when testing symptomatic patients. In asymptomatic populations, more research is needed to permit conclusions regarding their effectiveness for screening. BNP, RA size, presence of pericardial effusion, and uric acid had prognostic value in patients with PAH, but other echocardiographic parameters and biomarkers either were not predictive or had insufficient data. Although no studies were powered to detect a mortality reduction, monotherapy was associated with improved 6MWD and reduced hospitalization rates. Comparisons of different drug combinations were inconclusive regarding a mortality reduction but suggested an improvement in 6MWD when a second drug was added to existing monotherapy.
    MeSH term(s) Hypertension, Pulmonary/diagnostic imaging ; Hypertension, Pulmonary/therapy ; Ultrasonography ; Biomarkers ; Comparative Effectiveness Research ; Echocardiography ; Evidence-Based Medicine ; Outcome and Process Assessment (Health Care)
    Language English
    Size 1 online resource (1 PDF file (various pagings)) :, illustrations.
    Document type Book ; Online
    Note Title from PDF title page. ; "Contract No. 290-2007-10066-I."
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  5. Article ; Online: Time to question long-term safety of routine scheduled inhaled beta-2-agonist treatment for COPD.

    McCrory, Douglas C

    Journal of general internal medicine

    2006  Volume 21, Issue 10, Page(s) 1123–1124

    MeSH term(s) Administration, Inhalation ; Adrenergic beta-2 Receptor Agonists ; Adrenergic beta-Agonists/administration & dosage ; Adrenergic beta-Agonists/adverse effects ; Drug Administration Schedule ; Humans ; Pulmonary Disease, Chronic Obstructive/drug therapy ; Pulmonary Disease, Chronic Obstructive/pathology ; Time
    Chemical Substances Adrenergic beta-2 Receptor Agonists ; Adrenergic beta-Agonists
    Language English
    Publishing date 2006-10
    Publishing country United States
    Document type Comment ; Editorial
    ZDB-ID 639008-0
    ISSN 1525-1497 ; 0884-8734
    ISSN (online) 1525-1497
    ISSN 0884-8734
    DOI 10.1111/j.1525-1497.2006.00602.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Biofeedback as Prophylaxis for Pediatric Migraine: A Meta-analysis.

    Stubberud, Anker / Varkey, Emma / McCrory, Douglas C / Pedersen, Sindre Andre / Linde, Mattias

    Pediatrics

    2016  Volume 138, Issue 2

    Abstract: Context: Migraine is a common problem in children and adolescents, but few satisfactory prophylactic treatments exist.: Objective: Our goal was to investigate the pooled evidence for the effectiveness of using biofeedback to reduce childhood migraine. ...

    Abstract Context: Migraine is a common problem in children and adolescents, but few satisfactory prophylactic treatments exist.
    Objective: Our goal was to investigate the pooled evidence for the effectiveness of using biofeedback to reduce childhood migraine.
    Data sources: A systematic search was conducted across the databases Medline, Embase, CENTRAL, CINAHL, and PsychINFO.
    Study selection: Prospective, randomized controlled trials of biofeedback for migraine among children and adolescents were located in the search.
    Data extraction: Data on reduction of mean attack frequency and a series of secondary outcomes, including adverse events, were extracted. Risk of bias was also assessed.
    Results: Forest plots were created by using a fixed effects model, and mean differences were reported. Five studies with a total of 137 participants met the inclusion criteria. Biofeedback reduced migraine frequency (mean difference, -1.97 [95% confidence interval (CI), -2.72 to -1.21]; P < .00001), attack duration (mean difference, -3.94 [95% CI, -5.57 to -2.31]; P < .00001), and headache intensity (mean difference, -1.77 [95% CI, -2.42 to -1.11]; P < .00001) compared with a waiting-list control. Biofeedback demonstrated no adjuvant effect when combined with other behavioral treatment; neither did it have significant advantages over active treatment. Only 40% of bias judgments were deemed as "low" risk.
    Limitations: Methodologic issues hampered the meta-analyses. Only a few studies were possible to include, and they suffered from incomplete reporting of data and risk of bias.
    Conclusions: Biofeedback seems to be an effective intervention for pediatric migraine, but in light of the limitations, further investigation is needed to increase our confidence in the estimate.
    MeSH term(s) Adolescent ; Biofeedback, Psychology ; Child ; Humans ; Migraine Disorders/prevention & control ; Randomized Controlled Trials as Topic ; Waiting Lists
    Language English
    Publishing date 2016
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Research Support, Non-U.S. Gov't
    ZDB-ID 207677-9
    ISSN 1098-4275 ; 0031-4005
    ISSN (online) 1098-4275
    ISSN 0031-4005
    DOI 10.1542/peds.2016-0675
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: WITHDRAWN: Oral sumatriptan for acute migraine.

    McCrory, Douglas C / Gray, Rebecca N

    The Cochrane database of systematic reviews

    2012  , Issue 2, Page(s) CD002915

    Abstract: Background: Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective ... ...

    Abstract Background: Migraine is a common neurovascular disorder characterized by recurrent episodes of disabling headache, autonomic nervous system dysfunction, and, in some patients, neurological aura symptoms. Sumatriptan is one of a class of selective serotonin 5-hydroxytryptamine (5-HT1B/1D) agonists (triptans) thought to relieve migraine attacks by several mechanisms, including cranial vasoconstriction and peripheral and central neural inhibition.
    Objectives: To describe and assess the evidence from randomized controlled trials (RCTs) concerning the efficacy and tolerability of oral sumatriptan for the treatment of a single acute attack of migraine in adults.
    Search methods: We searched the Cochrane Central Register of Controlled Trials (Cochrane Library, Issue 4, 2001), MEDLINE (1966 through November 2001), and reference lists of articles and books.
    Selection criteria: We included double-blind RCTs comparing oral sumatriptan (100 mg, 50 mg, 25 mg) with placebo, no intervention, other drug treatments, behavioral therapy, or physical therapy for the treatment of an acute attack of migraine in adults. Trials comparing different doses of sumatriptan or dosing regimens were also included. Outcomes considered were: 2-hour pain-free response, headache relief/headache intensity, and functional disability; headache recurrence; and adverse events.
    Data collection and analysis: Data were abstracted by one reviewer and over-read by the other. The two reviewers independently assessed trial quality. Information on adverse events was collected from trial reports.
    Main results: Twenty-five trials involving 16,200 participants were included. Methodological quality was generally good. Sixteen trials were placebo comparisons and showed that sumatriptan in doses of 100 mg (14 trials), 50 mg (five trials), and 25 mg (three trials) provided significantly better pain-free response (100 mg and 25 mg only), headache relief, and relief of disability at 2 hours. Numbers-needed-to-treat (NNTs) for pain-free response at 2 hours were 5.1 (3.9 to 7.1) for the 100-mg dose (n = 2221) and 7.5 (2.7 to 142) for the 25-mg dose (n = 131); there was no significant difference between the 50-mg dose and placebo for this outcome (n = 127). For headache relief at 2 hours, NNTs were 3.4 (3.0 to 4.0), 3.2 (2.4 to 5.1), and 3.4 (2.3 to 6.6) for sumatriptan 100 mg (n = 2940), 50 mg (n = 420), and 25 mg (n = 226), respectively. Precise estimates of the efficacy of the 50- and 25-mg doses relative to the 100-mg dose could not be obtained.Adverse events were more common with sumatriptan 100 mg than with placebo (risk difference [RD] = 0.14 [0.09 to 0.20]; number-needed-to-harm [NNH] = 7.1 [5.0 to 11.1]; n = 3172). RDs for the 50- and 25-mg vs. placebo comparisons were not statistically significant.
    Authors' conclusions: Oral sumatriptan has been shown to be an effective drug for the treatment of a single acute attack of migraine. It is well tolerated, though minor adverse events were not uncommon in the included trials. Other triptans were generally similar in efficacy and adverse events. Among non-triptan drugs, ergotamine + caffeine was significantly less effective than sumatriptan, and other drugs have been insufficiently studied to draw firm conclusions.
    MeSH term(s) Acute Disease ; Administration, Oral ; Adult ; Humans ; Migraine Disorders/drug therapy ; Randomized Controlled Trials as Topic ; Serotonin Receptor Agonists/administration & dosage ; Sumatriptan/administration & dosage
    Chemical Substances Serotonin Receptor Agonists ; Sumatriptan (8R78F6L9VO)
    Language English
    Publishing date 2012-02-15
    Publishing country England
    Document type Journal Article ; Review ; Systematic Review
    ISSN 1469-493X
    ISSN (online) 1469-493X
    DOI 10.1002/14651858.CD002915.pub2
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Book: Criteria to determine disability related to multiple sclerosis

    McCrory, Douglas C

    (Evidence report/technology assessment ; no. 100 ; AHRQ publication ; no. 04-E019-2)

    2004  

    Institution United States. / Agency for Healthcare Research and Quality.
    Duke University Evidence-based Practice Center
    Author's details prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-Based Practice Center ; investigators, Douglas C. McCrory ... [et al.]
    Series title Evidence report/technology assessment ; no. 100
    AHRQ publication ; no. 04-E019-2
    MeSH term(s) Multiple Sclerosis ; Disability Evaluation ; Social Security
    Keywords United States
    Language English
    Size 121 p. :, ill.
    Publisher U.S. Dept. of Health and Human Services, Agency for Healthcare Research and Quality
    Publishing place Rockville, MD
    Document type Book
    Note "May 2004."
    ISBN 9781587631528 ; 1587631520
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  9. Book: Management of allergic rhinitis in the working-age population

    McCrory, Douglas C

    (Evidence report/technology assessment, ; no. 67 ; AHRQ publication ; no. 03-E015)

    2003  

    Institution United States. / Agency for Healthcare Research and Quality.
    Duke University Evidence-based Practice Center
    Author's details prepared for Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services ; prepared by Duke Evidence-based Practice Center ; Douglas C. McCrory ... [et al.]
    Series title Evidence report/technology assessment, ; no. 67
    AHRQ publication ; no. 03-E015
    MeSH term(s) Rhinitis, Allergic, Perennial/therapy ; Rhinitis, Allergic, Seasonal/therapy ; Adult
    Language English
    Size viii, 380 p. :, ill. ;, 28 cm.
    Publisher U.S. Dept. of Health and Human Services, Public Health Service, Agency for Healthcare Research and Quality
    Publishing place Rockville, MD
    Document type Book
    Note "March 2003."
    ISBN 9781587630774 ; 158763077X
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

  10. Article ; Online: Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis.

    Uronis, Hope E / Ekström, Magnus P / Currow, David C / McCrory, Douglas C / Samsa, Gregory P / Abernethy, Amy P

    Thorax

    2015  Volume 70, Issue 5, Page(s) 492–494

    Abstract: We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register to determine whether oxygen relieves dyspnoea in mildly or non-hypoxemic COPD and included 18 randomised controlled trials (431 participants) in the meta-analysis using Cochrane ... ...

    Abstract We searched MEDLINE, EMBASE and the Cochrane Controlled Trials Register to determine whether oxygen relieves dyspnoea in mildly or non-hypoxemic COPD and included 18 randomised controlled trials (431 participants) in the meta-analysis using Cochrane methodology. Oxygen therapy reduced dyspnoea when compared with medical air; standardised mean difference -0.37 (95% CI -0.50 to -0.24; I(2)=14%). In a priori subgroup and sensitivity analyses, dyspnoea was reduced by continuous oxygen during exertion but not short-burst oxygen therapy. Continuous exertional oxygen can relieve dyspnoea in mildly or non-hypoxemic COPD, but evidence from larger clinical trials is needed.
    MeSH term(s) Dyspnea/etiology ; Dyspnea/therapy ; Home Care Services ; Humans ; Oxygen Inhalation Therapy ; Pulmonary Disease, Chronic Obstructive/complications ; Pulmonary Disease, Chronic Obstructive/therapy
    Language English
    Publishing date 2015-05
    Publishing country England
    Document type Journal Article ; Meta-Analysis ; Research Support, N.I.H., Extramural ; Research Support, U.S. Gov't, P.H.S. ; Review
    ZDB-ID 204353-1
    ISSN 1468-3296 ; 0040-6376
    ISSN (online) 1468-3296
    ISSN 0040-6376
    DOI 10.1136/thoraxjnl-2014-205720
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top